Can a patient receiving osimertinib safely undergo dental crown placement without interrupting the medication?

Osimertinib and Dental Crown Work

Patients receiving osimertinib can safely undergo dental crown placement without interrupting the medication. Crown work is a minor dental procedure that does not require discontinuation of osimertinib.

Rationale for Continuing Osimertinib

The evidence strongly supports continuing antiplatelet and antithrombotic agents during minor dental procedures, and this principle extends to targeted cancer therapies like osimertinib:

• Minor dental procedures can be performed safely without stopping antiplatelet drugs 1, 2. The 2007 AHA/ACC/SCAI/ACS/ADA Science Advisory specifically states that "many of these procedures (eg, minor surgery, teeth cleaning, and tooth extraction) can likely be performed at no or only minor risk of bleeding" and notes "there are no well-documented cases of clinically significant bleeding after dental procedures, including multiple dental extractions" in patients on antiplatelet therapy 1.

• The 2022 CHEST guidelines recommend continuing antiplatelet drugs during minor dental procedures 2, emphasizing that local hemostatic measures (absorbable gelatin sponge, sutures) effectively manage any bleeding risk.

• Crown preparation is less invasive than tooth extraction, involving minimal soft tissue manipulation and no bone exposure. If extractions can be performed safely on antiplatelet therapy, crown work poses even less risk.

Critical Considerations Specific to Osimertinib

While osimertinib itself does not increase bleeding risk like antiplatelet agents, there are important oncologic considerations:

Do NOT interrupt osimertinib therapy for dental crown work because:

1. Maintaining continuous EGFR inhibition is critical - Osimertinib provides continuous suppression of EGFR-mutant cancer cells. Treatment interruptions could allow disease progression 3, 4, 5.

2. The drug has a 48-hour half-life 6 - Any interruption would require extended time off therapy to meaningfully reduce drug levels, creating unnecessary cancer progression risk.

3. No bleeding risk from osimertinib - The FDA label does not list bleeding or coagulopathy as adverse effects 6. The primary concerns are interstitial lung disease, QTc prolongation, and cardiomyopathy - none relevant to dental procedures.

Important Caveat: Medication-Related Osteonecrosis of the Jaw (MRONJ)

Be aware that osimertinib has been associated with MRONJ in case reports 7, 8:

• Two published cases document MRONJ developing in patients on osimertinib monotherapy (without bisphosphonates or denosumab) 7, 8
• The mechanism may involve reduced osteoclast differentiation and inhibited angiogenesis 7
• MRONJ typically presents with bone exposure, pain, and delayed healing after invasive dental procedures

For crown work specifically:

• Crown preparation involves minimal bone trauma compared to extractions or implants
• The MRONJ risk is primarily associated with invasive dentoalveolar surgery 9
• Ensure excellent oral hygiene and monitor healing carefully, but crown work can proceed

If more invasive dental work is needed:

• Coordinate closely between oncology and dentistry 7, 8
• Consider the cancer prognosis and urgency of dental treatment
• For elective invasive procedures, the MASCC/ISOO/ASCO guidelines suggest these "should not be performed during active therapy" with bone-modifying agents 9, though osimertinib is not a traditional bone-modifying agent

Practical Management Algorithm

For routine crown work:

1. Continue osimertinib without interruption
2. Ensure good oral hygiene before the procedure
3. Use local hemostatic measures as needed during crown preparation
4. Monitor healing at routine follow-up (no special precautions needed)

For more invasive dental procedures (extractions, implants):

1. Discuss with the oncology team given MRONJ case reports
2. Weigh cancer control urgency against dental procedure urgency
3. If proceeding, maintain close monitoring for delayed healing or bone exposure
4. Generally continue osimertinib unless oncologist determines brief interruption is safe

The bottom line: Crown work poses minimal risk and should proceed with osimertinib continued.